November 2023

Risco de Eventos Cardiovasculares Adversos Maiores em Distúrbios Inflamatórios Imunomediados com Biológicos e Moléculas Pequenas: Meta-análise em rede

Clin Gastroenterol Hepatol. 2023 Oct 9:S1542-3565(23)00767-X doi 10.1016/j.cgh.2023.09.033 Epub ahead of print

The results of this study show that anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with slightly higher risk of MACE compared with placebo. The risk was no different between biologic treatments, and the magnitude of risk did not differ between IMID type.

Keywords:

April 2023

Associação entre Imunoterapia Biológica para Psoríase e Tempo para Artrite Inflamatória Incidente: Um estudo de coorte retrospectivo

Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6

Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.

March 2023

Diferenças Específicas de Gênero em Pacientes com Artrite Psoriásica Recebendo Ustekinumabe ou Inibidores de Fator de Necrose Tumoral: dados de mundo real

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089

These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.

Keywords: